Results 181 to 190 of about 5,337 (191)

Aducanumab: Boon or bust?

The Brown University Psychopharmacology Update, 2021
openaire   +1 more source

Aducanumab for the treatment of Alzheimer's disease: a systematic review

Psychogeriatrics, 2023
exaly  

Potential eligibility for Aducanumab therapy in an Irish specialist cognitive service—Utilising cerebrospinal fluid biomarkers and appropriate use criteria

International Journal of Geriatric Psychiatry, 2022
Zara Togher
exaly  

Aducanumab/donepezil/memantine

Reactions Weekly, 2023
openaire   +1 more source

Reply to “Thinking beyond Aducanumab Controversy”

Annals of Neurology, 2021
openaire   +2 more sources

AGS Perspective: AGS in Action, Aducanumab

Journal of Gerontological Nursing, 2021
openaire   +2 more sources

Aducanumab for Alzheimer's Disease: Summarized Data From EMERGE, ENGAGE, and PRIME Studies

2022
exaly  

Results from the long‐term extension of PRIME: A randomized Phase 1b trial of aducanumab

Alzheimer's and Dementia
John O'Gorman, Alfred Sandrock
exaly  

Mining and analysis of adverse events associated with aducanumab: a real-world study using FDA Adverse Event Reporting System database

Expert Opinion on Drug Safety
Cheng Jiang
exaly  

Aducanumab (Aduhelm) for Alzheimer's disease.

The Medical letter on drugs and therapeutics, 2021
openaire   +1 more source